Swiss pharma giant Novartis (NOVN: VX) has entered into an exclusive license agreement with two biotech companies – Belgo-Dutch Galapagos (Euronext: GLPG) and Germany’s MorphoSys (FSE: MOR) - regarding their atopic dermatitis compound MOR106.
Under the agreement, Novartis acquires the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Novartis will make an up-front payment of 95 million euros ($111 million) and potential milestone payments of up to around 850 million euros ($1 billion) plus royalties up to low-teens to low-twenties. Payments will be split 50:50 between the companies.
News of the deal saw Galapagos’ shares rise 2.21% to 89.86 euros and those of MorphoSys gained 3.71% to 117.40 in early trading this morning.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze